Focus on citalopram: A selective reuptake inhibitor for the treatment of depression

Published

Journal Article (Review)

Citalopram is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA for the treatment of major depression. Pharmacologically, it has higher serotonin selectivity than other marketed SSRIs. Clinical trials in a variety of practice settings and depressed populations show citalopram to be effective and well tolerated. The drug lacks significant side effects commonly noted with tricyclic antidepressants, such as orthostatic hypotension. Its adverse effect profile is similar to those of other SSRIs, with nausea most commonly reported. Currently, few drug interactions have been documented with citalopram. Some data suggest that citalopram inhibits the cytochrome P450 isoenzyme system, particularly the 2D6 isoenzyme, less potently than the other SSRIs do. As such, it decreases the potential for drug interactions, making it an appealing option for treating depression in primary care and in the elderly.

Duke Authors

Cited Authors

  • Scates, AC; Doraiswamy, PM

Published Date

  • December 1, 1998

Published In

Volume / Issue

  • 33 / 8

Start / End Page

  • 725 - 743

International Standard Serial Number (ISSN)

  • 1082-801X

Citation Source

  • Scopus